Taken together, our findings suggested that the disruption of the circTLK1/miR-16-5p/Smad3 positive feedback pathway, particularly via the Smad3 inhibitor SIS3, could be a promising therapeutic strategy.
The malignancy of chordomas is enhanced via a circTLK1/miR-16-5p/Smad3 positive feedback axis.